Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

Cancer Cell

Volumn 13, Issue 4, 2008, Pages 311-320

  Wernig, Gerlinde ^a   Kharas, Michael G ^a   Okabe, Rachel ^a   Moore, Sandra A ^a   Leeman, Dena S ^a   Cullen, Dana E ^a   Gozo, Maricel ^a   McDowell, Elizabeth P ^a   Levine, Ross L ^a,b   Doukas, John ^d   Mak, Chi Ching ^d   Noronha, Glenn ^d   Martin, Michael ^d   Ko, Yon D ^e   Lee, Benjamin H ^a   Soll, Richard M ^d   Tefferi, Ayalew ^f   Hood, John D ^d   Gilliland, D Gary ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d TargeGen Inc ^*  (United States)

^e Johanniter KH   (Germany)

^f MAYO CLINIC   (United States)

Author keywords

CELLCYCLE; CHEMBIO

Indexed keywords

JANUS KINASE 2; JANUS KINASE INHIBITOR; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (PYRROLIDIN 1 YL)ETHOXY]PHENYLAMINO]PYRIMIDIN 4 YLAMINO]BENZENESULFONAMIDE; PLACEBO; STAT PROTEIN; STAT5 PROTEIN; TG 101348; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLONY FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; EMBRYO; ENZYME INHIBITION; FLOW CYTOMETRY; GENE; GENE MUTATION; GENOMICS; HEMATOCRIT; HEMATOPOIESIS; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MOUSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

ANIMALIA; MURINAE;

EID: 41249099841     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.02.009     Document Type: Article

References (23)

1. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347 (2002) 481-487
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
3. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348 (2003) 1201-1214
4. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344 (2001) 1038-1042
5. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 (2001) 1031-1037
6. Harrison C.N., Campbell P.J., Buck G., Wheatley K., East C.L., Bareford D., Wilkins B.S., van der Walt J.D., Reilly J.T., Grigg A.P., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353 (2005) 33-45
7. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
8. Kiladjian J.J., Cassinat B., Turlure P., Cambier N., Roussel M., Bellucci S., Menot M.L., Massonnet G., Dutel J.L., Ghomari K., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108 (2006) 2037-2040
9. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., Tichelli A., Cazzola M., and Skoda R.C. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
10. Krutzik P.O., and Nolan G.P. Intracellular phospho-protein staining techniques for flow cytometry: Monitoring single cell signaling events. Cytometry A 55 (2003) 61-70
11. Lacout C., Pisani D.F., Tulliez M., Gachelin F.M., Vainchenker W., and Villeval J.L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
12. Levine R.L., Belisle C., Wadleigh M., Zahrieh D., Lee S., Chagnon P., Gilliland D.G., and Busque L. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 107 (2006) 4139-4141
13. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
14. Lu X., Levine R., Tong W., Wernig G., Pikman Y., Zarnegar S., Gilliland D.G., and Lodish H. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. USA 102 (2005) 18962-18967
15. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
16. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
17. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., Cuker A., Wernig G., Moore S., Galinsky I., et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med. 3 (2006) e270 10.1371/journal.pmed.0030270
18. Prchal J.F., and Axelrad A.A. Letter: Bone-marrow responses in polycythemia vera. N. Engl. J. Med. 290 (1974) 1382
19. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356 (2007) 459-468
20. Tefferi A., Cortes J., Verstovsek S., Mesa R.A., Thomas D., Lasho T.L., Hogan W.J., Litzow M.R., Allred J.B., Jones D., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108 (2006) 1158-1164
21. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358 (2001) 1421-1423
22. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4281
23. Zaleskas V.M., Krause D.S., Lazarides K., Patel N., Hu Y., Li S., and Van Etten R.A. Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F. PLoS ONE 1 (2006) e18 10.1371/journal.pone.0000018